Drug intelligence / Profile preview

peluntamig + carboplatin + etoposide

Development stage: Unknown
Lead developer: Phanes Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

**Peluntamig + carboplatin + etoposide** is an investigational combination therapy studied for the treatment of advanced or refractory cancers, especially extensive-stage small cell lung cancer (ES-SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC), and extrapulmonary neuroendocrine carcinoma (EP-NEC). **Peluntamig (PT217)** is a first-in-class bispecific antibody targeting **Delta-like protein 3 (DLL3)**, involved in tumor growth through the Notch signaling pathway, and **CD47**, which sends a "don't eat me" signal to immune cells (SIRPalpha interaction), thereby helping cancer cells evade immune surveillance[1][2][4]. Carboplatin and etoposide are standard platinum-based chemotherapeutic agents commonly used in the management of small cell lung cancer[5]. This combination therapy is being evaluated for enhanced anti-tumor efficacy, leveraging both immune-mediated (peluntamig) and cytotoxic (carboplatin + etoposide) mechanisms. The development includes orphan drug and fast track designations for SCLC, NEC, and neuroendocrine prostate cancer[2][4].

Other names: peluntamig + carboplatin + etoposide

Targets

CD47 (Cluster of Differentiation 47)DLL3 (Delta-like ligand 3)DNA

Beyond the preview

Go deeper on peluntamig + carboplatin + etoposide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on peluntamig + carboplatin + etoposide.

Explore the full profile